Identifying polyglutamine protein species in situ that best predict neurodegeneration

Gladstone Institute of Neurological Disease, San Francisco, California, USA.
Nature Chemical Biology (Impact Factor: 13). 12/2011; 7(12):925-34. DOI: 10.1038/nchembio.694
Source: PubMed


Polyglutamine (polyQ) stretches exceeding a threshold length confer a toxic function to proteins that contain them and cause at least nine neurological disorders. The basis for this toxicity threshold is unclear. Although polyQ expansions render proteins prone to aggregate into inclusion bodies, this may be a neuronal coping response to more toxic forms of polyQ. The exact structure of these more toxic forms is unknown. Here we show that the monoclonal antibody 3B5H10 recognizes a species of polyQ protein in situ that strongly predicts neuronal death. The epitope selectively appears among some of the many low-molecular-weight conformational states assumed by expanded polyQ and disappears in higher-molecular-weight aggregated forms, such as inclusion bodies. These results suggest that protein monomers and possibly small oligomers containing expanded polyQ stretches can adopt a conformation that is recognized by 3B5H10 and is toxic or closely related to a toxic species.

Download full-text


Available from: Justin Legleiter
  • Source
    • "To enable such therapeutic programs it is crucial that the HTT protein be quantified in a reliable and robust manner to determine the pharmacodynamic effects of such potential therapeutics. To date, this has been difficult due to the structural complexity of the large HTT protein which exists in several conformers and states including soluble monomers, intermediate fibrils, insoluble aggregates, as well as several possible cleavage products [12], [13]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The expansion of a CAG trinucleotide repeat in the huntingtin gene, which produces huntingtin protein with an expanded polyglutamine tract, is the cause of Huntington's disease (HD). Recent studies have reported that RNAi suppression of polyglutamine-expanded huntingtin (mutant HTT) in HD animal models can ameliorate disease phenotypes. A key requirement for such preclinical studies, as well as eventual clinical trials, aimed to reduce mutant HTT exposure is a robust method to measure HTT protein levels in select tissues. We have developed several sensitive and selective assays that measure either total human HTT or polyglutamine-expanded human HTT proteins on the electrochemiluminescence Meso Scale Discovery detection platform with an increased dynamic range over other methods. In addition, we have developed an assay to detect endogenous mouse and rat HTT proteins in pre-clinical models of HD to monitor effects on the wild type protein of both allele selective and non-selective interventions. We demonstrate the application of these assays to measure HTT protein in several HD in vitro cellular and in vivo animal model systems as well as in HD patient biosamples. Furthermore, we used purified recombinant HTT proteins as standards to quantitate the absolute amount of HTT protein in such biosamples.
    Full-text · Article · May 2014 · PLoS ONE
  • Source
    • ") and, in a mechanistic parallel with the pathogenic mechanisms proposed for " classical " amyloids, many studies suggested that the insoluble inclusions played a protective role, sequestering toxic, and misfolded protein conformers (Arrasate et al., 2004; Rub et al., 2006; Miller et al., 2010). Indeed, soluble intermediates in the aggregation pathway such as misfolded β-sheet rich polyQ protein monomers and oligomers have latter been identified and proposed to represent the major toxic species (Kayed et al., 2003; Gales et al., 2005; Nagai et al., 2007; Miller et al., 2011). Also, in OPMD, the primary toxic species are proposed to be the soluble variants of the expanded polyA-repeat protein PABPN1 (Messaed et al., 2007). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Trinucleotide repeat (TNR) expansions are present in a wide range of genes involved in several neurological disorders, being directly involved in the molecular mechanisms underlying pathogenesis through modulation of gene expression and/or the function of the RNA or protein it encodes. Structural and functional information on the role of TNR sequences in RNA and protein is crucial to understand the effect of TNR expansions in neurodegeneration. Therefore, this review intends to provide to the reader a structural and functional view of TNR and encoded homopeptide expansions, with a particular emphasis on polyQ expansions and its role at inducing the self-assembly, aggregation and functional alterations of the carrier protein, which culminates in neuronal toxicity and cell death. Detail will be given to the Machado-Joseph Disease-causative and polyQ-containing protein, ataxin-3, providing clues for the impact of polyQ expansion and its flanking regions in the modulation of ataxin-3 molecular interactions, function, and aggregation.
    Full-text · Article · Jun 2013 · Frontiers in Neurology
  • Source
    • "Although nuclear inclusions are a disease-specific histopathological finding, they may not be pathogenic per se. Monomers and soluble oligomers of the expanded protein may constitute the toxic species in polyglutamine diseases, and the intranuclear inclusions likely represent a protective response to the abnormal polyglutamine protein (Arrasate et al, 2004; Miller et al, 2011). Although the expansion may interfere with the normal function of the host protein, it is not yet clear how this contributes to pathogenesis. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Spinal and bulbar muscular atrophy, or Kennedy's disease, is an X-linked motor neuron disease caused by polyglutamine repeat expansion in the androgen receptor. The disease is characterised by weakness, atrophy and fasciculations in the limb and bulbar muscles. Affected males may have signs of androgen insensitivity, such as gynaecomastia and reduced fertility. Neurophysiological studies are typically consistent with diffuse denervation atrophy, and serum creatine kinase is usually elevated 2-5 times above normal. Progression of the disease is slow, and the focus of spinal and bulbar muscular atrophy (SBMA) management is to prevent complications.
    Preview · Article · Apr 2013 · Oral Diseases
Show more